Image
Clinical Research Updates™

Clinical Updates in Rheumatoid Arthritis

New Perspectives on Targeting Remission and Individualizing Therapy

Clinical Practice Guidelines

2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis.

Singh JA, et al. Arthritis Rheumatol. 2016;68(1):1-26.

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Smolen JS, et al. Ann Rheum Dis. 2013;72(4):482-492.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, et al. Ann Rheum Dis. 2017;76(6):960-977.

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Smolen JS, et al. Ann Rheum Dis. 2016;75(1):3-15.

Patient Resources

American College of Rheumatology Disease Overview

The American College of Rheumatology has published a concise overview to help patients and caregivers learn more about rheumatoid arthritis and to provide tips for living well with this rheumatic disease.

American College of Rheumatology Patient Education Videos

The American College of Rheumatology has produced a library of videos about the impact of rheumatic disease, what to do when diagnosed with rheumatic disease, when to see a rheumatologist, and what patients have to say about their experiences of living with rheumatic disease.

Arthritis Foundation

The Arthritis Foundation provides self-care tools and resources covering treatment options, pain management, diet and exercise, and common comorbidities associated with many different arthritic conditions.

Handout on Health: Rheumatoid Arthritis

A publication from the National Institute of Arthritis and Musculoskeletal and Skin Diseases for people who have rheumatoid arthritis, as well as for their family members, friends, and others who want to find out more about this disease.

Rheumatoid Arthritis Support Network

The Rheumatoid Arthritis Support Network provides up-to-date information for patients with rheumatoid arthritis, including links to patient support groups, blogs written by patients with rheumatoid arthritis, resources to help pay for medications, and smart device apps to help track symptoms over time.

Suggested Readings

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.

McInnes IB, et al. Ann Rheum Dis. 2015;74(4):694-702.

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.

Burmester GR, et al. Ann Rheum Dis. 2017;76(5):840-847.

IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.

Kim GW, et al. Arch Pharm Res. 2015;38(5):575-584.

Measures of rheumatoid arthritis disease activity.

Anderson JK, et al. Arthritis Care Res (Hoboken). 2011;63(suppl 11):S14-S36.

The pathogenesis of rheumatoid arthritis.

McInnes IB, Schett G. N Engl J Med. 2011;365(23):2205-2219.

Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.

Anderson J et al. Arthritis Care Res (Hoboken). 2012;64(5):640-647.

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.

Strand V, et al. RMD Open. 2017;3(1):e000416.

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study.

Genovese MC, et al. Arthritis Rheumatol. 2015;67(6):1424-1437.

Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors.

Fleischmann R, et al. Arthritis Rheumatol. 2017;69(2):277-290.

Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.

Dennis G Jr, et al. Arthritis Res Ther. 2014;16(2):R90.

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.

Burmester GR, et al. Ann Rheum Dis. 2016;75(6):1081-1091.

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.

Kremer JM, et al. Arthritis Rheum. 2011;63(3):609-621.

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

Gabay C, et al. Lancet. 2013;381(9877):1541-1550.

Activity
Clinical Updates in Rheumatoid Arthritis

New Perspectives on Targeting Remission and Individualizing Therapy

Relevant Resources

Clinical Updates in Systemic Lupus Erythematosus

Improved Diagnostic and Management Strategies

Advances in Immunosupressive Therapy for Solid Organ Transplantation

Long-Term Management Strategies to Improve Patient Outcomes

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Improving Outcomes in Rheumatoid Arthritis

Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Going Deeper on Atopic Dermatitis

Pathophysiology to the Management of Moderate-to-Severe Disease

Looking Beneath The Surface In Atopic Dermatitis

Targeting Immune Dysregulation and Delivering Comprehensive Care

Evolving Treatment Paradigms For Rheumatoid Arthritis

Translating Comprehensive Patient Evaluations Into Personalized Therapy

A Better Look at Rheumatoid Arthritis

Using Imaging to Improve Patient Outcomes

Clinical Issues in Rheumatoid Arthritis

Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs